Genotypic prediction of tuberculosis drug resistance and implementation of effective MDR-TB management

Leading partner organisation: FZB (Germany)

An effective approach to the management of MDR-TB is to tailor drug therapy regimens on the basis of comprehensive resistance testing. CARE will contribute to this effort by:

  • Helping elucidate MDR-TB epidemiology in Russia and Moldova

  • Developing a genotype-to-phenotype prediction framework based on whole genome sequencing to infer second-line TB drug resistance from genotypic data and ease the choice of personalised treatment

  • Designing and developing a software tool for phenotypic drug resistance prediction by genotype

  • Characterizing host genetic traits that predispose to extrapulmonary TB and are known to be involved in higher susceptibility to HIV

  • Defining and testing a pilot model intervention of personalised effective MDR-TB treatment in Russia and other countries of the former Soviet Union, and designing associated clinical training modules

Heading 1

Heading 1

Heading 1

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825673.

Subscribe to the CARE newsletter
CONTACTS

Francesca Incardona

 

f.incardona@euresist.org